<DOC>
	<DOCNO>NCT02979951</DOCNO>
	<brief_summary>The purpose European , multicentric , prospective , non-interventional study document evaluate efficacy safety treatment severely infected patient intravenously administer fosfomycin , include patient osteomyelitis , complicate urinary tract infection , nosocomial low respiratory tract infection , bacterial meningitis/central nervous system infection , bacteraemia/sepsis , skin soft tissue infection , endocarditis infection , far covered respective nationally relevant SmPC .</brief_summary>
	<brief_title>Fosfomycin i.v . Treatment Severely Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Urinary Tract Infections</mesh_term>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Bacteremia</mesh_term>
	<mesh_term>Abscess</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Skin Diseases</mesh_term>
	<mesh_term>Osteomyelitis</mesh_term>
	<mesh_term>Endocarditis</mesh_term>
	<mesh_term>Soft Tissue Infections</mesh_term>
	<mesh_term>Pneumonia , Bacterial</mesh_term>
	<mesh_term>Skin Diseases , Bacterial</mesh_term>
	<mesh_term>Intraabdominal Infections</mesh_term>
	<mesh_term>Bone Diseases , Infectious</mesh_term>
	<mesh_term>Meningitis , Bacterial</mesh_term>
	<mesh_term>Endocarditis , Bacterial</mesh_term>
	<mesh_term>Brain Abscess</mesh_term>
	<mesh_term>Central Nervous System Bacterial Infections</mesh_term>
	<mesh_term>Fosfomycin</mesh_term>
	<criteria>Male female patient age â‰¥ 18 year Treatment fosfomycin accord ( national ) Summary Product Characteristics ( SmPC ) fosfomycin i.v . Patients osteomyelitis , complicate urinary tract infection , nosocomial low respiratory tract infection , bacterial meningitis/central nervous system infection , bacteraemia/sepsis , skin soft tissue infection , endocarditis infection , far covered respective nationally relevant SmPC Written inform consent participant ( person charge case patient incapable give consent ) Previous documentation patient present study Patients participate interventional clinical trial Patients know hypersensitivity fosfomycin excipients Terminally ill patient Patients `` resuscitate order '' Palliative treatment approach Failure &gt; 3 follow organ system : respiratory system , nervous system , cardiovascular system , liver , coagulation , kidney Manifest Human Immunodeficiency Virus ( HIV ) disease ( Acquired Immunodeficiency Syndrome , AIDS ) Fosfomycin treatment 4th line treatment later stage Patients involvement fungi mycobacteria target infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Observational Study</keyword>
	<keyword>Non-Interventional Study</keyword>
	<keyword>Registries</keyword>
	<keyword>Prospective</keyword>
	<keyword>Monitored</keyword>
	<keyword>Multicentric</keyword>
	<keyword>International</keyword>
	<keyword>Fosfomycin</keyword>
	<keyword>Infectofos</keyword>
	<keyword>Fomicyt</keyword>
	<keyword>Bacterial Infections</keyword>
	<keyword>Gram-Negative Bacterial Infections</keyword>
	<keyword>Gram-Positive Bacterial Infections</keyword>
	<keyword>Bone Diseases , Infectious</keyword>
	<keyword>Osteomyelitis</keyword>
	<keyword>Central Nervous System Bacterial Infections</keyword>
	<keyword>Meningitis , Bacterial</keyword>
	<keyword>Encephalitis</keyword>
	<keyword>Brain Abscess</keyword>
	<keyword>Urinary Tract Infections</keyword>
	<keyword>Respiratory Tract Infections</keyword>
	<keyword>Pneumonia , Bacterial</keyword>
	<keyword>Skin Diseases , Bacterial</keyword>
	<keyword>Soft Tissue Infections</keyword>
	<keyword>Intraabdominal Infections</keyword>
	<keyword>Sepsis</keyword>
	<keyword>Bacteremia</keyword>
	<keyword>Endocarditis , Bacterial</keyword>
	<keyword>Treatment Outcome</keyword>
	<keyword>Clinical Efficacy</keyword>
	<keyword>Microbiological Efficacy</keyword>
	<keyword>Safety</keyword>
</DOC>